Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society - Summary - MDSpire
Advertisement
Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society
To provide region-specific guidelines for the diagnosis and management of hidradenitis suppurativa (HS) in the UAE, addressing its significant impact on patient quality of life.
Key Findings:
HS is a chronic inflammatory condition affecting the pilosebaceous unit, primarily in apocrine gland-bearing areas.
The prevalence of HS is challenging to estimate due to misdiagnosis and underdiagnosis, with significant implications for patient care.
HS significantly impacts patients' quality of life and is associated with mental health issues, necessitating comprehensive management strategies.
Interpretation:
The guidelines aim to standardize HS care in the UAE, addressing regional disparities and improving treatment outcomes through evidence-based clinical pathways, ultimately enhancing patient quality of life.
Limitations:
The consensus may not fully reflect all local variations in HS presentation and management, and potential biases in expert selection could affect the consensus.
Limited data on HS prevalence and burden in the UAE may affect the applicability of the guidelines.
Conclusion:
The consensus provides a structured approach to HS management in the UAE, aiming to enhance care quality and patient outcomes, with an emphasis on the importance of multidisciplinary care.
Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.
